To the Editor. —We read with interest Akpinar's recent report (Archives 1982;39:739) on the beneficial effect of a levodopa-benserazide combination in relieving restless legs syndrome. That this drug regimen has not produced insomnia in their patients is noteworthy. Large doses of levodopa are known to increase waking time1 and to decrease rapid eye movement sleep2 in normal subjects. Because restless legs syndrome appears only at rest, and mostly before bedtime, a treatment that facilitates sleep may be more appropriate for this condition.It has been reported that certain benzodiazepines, especially clonazepam, relieve restless legs syndrome dramatically.3,4 In our animal model for myoclonus, in which the myclonic jerks are localized in the hind quarter (and hence resemble restless legs syndrome more closely than does myoclonus), clonazepam and flunitrazepam were 33 and 116 times more effective than diazepam, respectively, in blocking these jerks.5 This finding warrants the clinical
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Archives of Neurology editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.